ClinicalTrials.gg
CompletedNCT02707913Updated Sep 7, 2016

Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations

A Phase 1 interventional study of BF-Amlodipine Tablet 10mg and Norvasc Tablet 10mg in Healthy, sponsored by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-07.

Sponsored by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to compare the bioavailability of a generic product of amlodipine with that of a reference product when administered to healthy volunteers under fasting conditions. The test product name is BF-Amlodipine Tablet 10mg manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited, and the reference product is Norvasc Tablet 10mg. The plasma pharmacokinetic data of amlodipine obtained from two formulations will be used to access the interchangeability of the products

Read the detailed description

The study design is a single-dose, two-treatment, two-period, two-sequence crossover with a washout period of two to three weeks. During each session, the subjects will be administered a single oral dose of 10mg amlodipine (one BF-Amlodipine Tablet 10mg or one Norvasc Tablet 10mg) after an overnight fast of approximately 10 hours. Venous blood samples will be collected at pre-dose (0 h), and up to 96 h post dose. The plasma concentrations of amlodipine will be determined by a validated assay. The non-compartmental method will be used to analyze the plasma concentration-time data and calculate the main pharmacokinetic parameters such as Peak plasma concentration (Cmax), Time to maximum concentration (Tmax), Area under the plasma concentration versus time curve (AUC0-last, AUC0-inf) and Elimination half-life (T1/2). Analysis of Variance (ANOVA) will be conducted on logarithmically transformed Cmax, AUC0-last and AUC0-inf. The two one sided tests will be used to calculate the 90% confidence intervals for the mean difference in AUC0-last, AUC0-inf and Cmax, and to assess the bioequivalence of the two products

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 to 27
  • Accessible vein for blood sampling
  • High probability for compliance and completion of the study
  • No significant abnormalities in general physical examination
  • (ECG) recording within normal limits
  • Biochemical and haematological parameters within normal limits
  • Subjects must agree to take effective methods to prevent pregnancy from the start of screening until two weeks of last dose administration

Exclusion criteria

Exclusion Criteria:

  • History of hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to the study
  • abnormality in physical examination, evaluation, urine test, blood chemistry and haematological test
  • Tobacco use in any forms
  • Regular consumer of alcohol
  • Blood donation within 4 weeks prior to the start of the study
  • Use of amlodipine within 4 weeks before the study
  • Use of antihypertensive medications within 4 weeks before the study
  • Volunteer in any other clinical drug study within 2 months prior to this study
  • to amlodipine or other drugs in its class
  • History of drug abuse in any form
  • Female subjects who are breastfeeding or pregnant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    BF-Amlodipine Tablet 10mg

    During the study session, healthy subjects will be administered a single dose of BF-Amlodipine Tablet 10mg after an overnight fast of approximately 10 hours

    Drug: BF-Amlodipine Tablet 10mg

  • Active comparator
    Norvasc Tablet 10mg

    During the study session, healthy subjects will be administered a single dose of Norvasc Tablet 10mg after an overnight fast of approximately 10 hours

    Drug: Norvasc Tablet 10mg

Interventions

  • BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

    Also known as: Amlodipine Tablet 10mg

  • Norvasc Tablet 10mg will be used as a comparator drug for the BE study

    Also known as: Amlodipine Tablet 10mg

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax) of amlodipine

    Time frame: 96 hours

  2. Area under the plasma concentration versus time curve (AUC) of amlodipine

    Time frame: 96 hours

Secondary outcomes

  1. Time to maximum concentration (Tmax) of amlodipine

    Time frame: 96 hours

  2. Elimination half-life (t1/2) of amlodipine)

    Time frame: 96 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Study investigators and his/her study team members, domestic and foreign regulatory agencies, the Institutional Review Board/Ethics Committee (IRB/EC) involved in the study, and laboratories and other individuals and organizations that analyze the subjects' protected health information in connection with this study have access to the data or study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Aug 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2016
First posted
Mar 14, 2016
Start
Mar 2016
Primary completionActual
Aug 2016
CompletionActual
Sep 2016
Last update
Sep 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02707913
Lead sponsor
Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
Responsible party
Sponsor
First posted
Mar 14, 2016
Start date
Mar 2016
Primary completion
Aug 2016
Completion
Sep 2016
Last update
Sep 7, 2016

Study contacts

Zhong ZUO
principal investigator · School of Pharmacy, The Chinese Univesity of Hong Kong
Risa Ozaki
study director · Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong
Brian Tomlinson
study director · Dept. of Medicine and Therapeutics, The Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion